Xlife Sciences Secures Key Vote for VERAXA's U.S. Listing Ambition

Xlife Sciences portfolio firm VERAXA Biotech AG secures 99.57% shareholder approval for its merger and planned NASDAQ listing, aiming to boost global visibility and capital access.

A decisive shareholder vote has paved the way for a significant strategic move by Xlife Sciences. The Swiss management company’s portfolio firm, VERAXA Biotech AG, has received overwhelming approval to proceed with its planned merger and subsequent listing on the NASDAQ exchange in the United States.

Unanimous Shareholder Backing for Strategic Pivot

The path to an international listing is now clear. Shareholders voted in favor of the proposed merger with a commanding majority of 99.57 percent. This near-unanimous support satisfies a critical formal requirement to launch the future public listing under the ticker symbol "VRXA."

For Xlife Sciences, this outcome represents a milestone in its ongoing portfolio strategy. The core objective is to unlock access to global capital platforms, thereby dramatically increasing the visibility and reach of the technologies developed within its portfolio. A successful U.S. debut could potentially serve as a model for scaling other companies under the Xlife Sciences umbrella.

Targeting the Premier Life Sciences Marketplace

The selection of the NASDAQ is a deliberate strategic choice, targeting the world's most significant marketplace for life sciences firms. By securing a U.S. listing, Xlife Sciences aims to accelerate the commercial rollout and industrial adoption of VERAXA's innovations. This initiative is part of a broader series of internationalization measures the company has undertaken in recent months.

Market reaction to the news has been measured. In the latest trading session, Xlife Sciences shares closed at 22.10 CHF, reflecting a single-day decline of 1.78 percent. The stock continues to trade in a consolidation phase below its 50-day moving average of 22.99 CHF. On a year-to-date basis, however, the equity shows a gain of 10.78 percent.

With the shareholder vote confirmed, the focus shifts to the anticipated commencement of trading on the NASDAQ. Investors will now closely monitor how the market values the new "VRXA" entity. A smooth transition to the U.S. exchange could establish a solid foundation for the parent company's share price, with the area around 21.02 CHF—the 200-day moving average—acting as a key support level.